Botulinum toxoid vaccine pivotal trial in guinea pigs supported by FDA advisory committee.
BOTULINUM TOXOID VACCINE PIVOTAL TRIAL IN GUINEA PIGS ACCEPTABLE, members of the Vaccines and Related Biological Products Advisory Committee agreed at an Oct. 30 meeting. The proposed U.S. Army study will involve obtaining immune globulin from volunteers given the botulinum vaccine. The human antibodies will be transferred to guinea pigs through intraperitoneal injection, and the animals will then be exposed to botulinum toxins and screened for immunity.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth